{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:03:56Z","timestamp":1787731436897,"version":"build-2784847793"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"UNSW Sydney University Postgraduate Award"},{"name":"Australian Government Research Training Program Scholarship"},{"name":"Australia and New Zealand Bone and Mineral Society and the Endocrine Society of Australia"},{"name":"Ernest Heine Family Foundation and Cancer Council","award":["R20-05"],"award-info":[{"award-number":["R20-05"]}]},{"name":"American Society of Bone and Mineral Research Rising Star"},{"name":"Bone Health Foundation"},{"DOI":"10.13039\/501100022883","name":"Australia and New Zealand Bone and Mineral Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022883","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Rebound bone loss following denosumab discontinuation is an important barrier in the effective long-term treatment of skeletal disorders. This is driven by increased osteoclastic bone resorption following the offset of RANKL inhibition, and sequential osteoclast-directed therapy has been utilized to mitigate this. However, current sequential treatment strategies intervene following the offset of RANKL inhibition and this approach fails to consistently prevent bone loss. Our previous work, using a mouse model of denosumab discontinuation, has shown that the processes that drive the rebound phenomenon occur earlier than when bone loss is detected, namely a rise and overshoot in serum tartrate-resistant acid phosphatase (TRAP). We identified that these changes in serum TRAP may provide an earlier window of opportunity to intervene with sequential therapy following RANKL inhibition withdrawal. Here, we show that early treatment with zoledronate (10\u00a0mg\/kg, 3\u00a0wk following the last dose of OPG:Fc), preceding the rise and overshoot in serum TRAP, effectively mitigates rebound bone density loss through preventing the overshoot in serum TRAP. Further, we show that multiple doses of zoledronate (early treatment and during anticipated BMD loss) is superior in consolidating bone density gains made with RANKL inhibition and preventing rebound BMD loss as measured by DXA. Importantly, we demonstrate the efficacy of early and multi-dose zoledronate strategy in preventing bone loss in both growing and skeletally mature mice. MicroCT analysis showed improved trabecular bone structure in both the femur and lumbar vertebrae with zoledronate treatment compared with control. These increases in bone mass translated to increased fracture resistance in skeletally mature mice. This work provides a novel approach of early and multi-dose sequential treatment strategy following withdrawal of RANKL inhibition, contributing valuable insight into the clinical management of patients who discontinue denosumab therapy.<\/jats:p>","DOI":"10.1093\/jbmr\/zjaf008","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T04:21:52Z","timestamp":1737606112000},"page":"413-427","source":"Crossref","is-referenced-by-count":11,"title":["Early and multiple doses of zoledronate mitigates rebound bone loss following withdrawal of receptor activator of nuclear factor kappa-B ligand inhibition"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5832-0224","authenticated-orcid":false,"given":"Albert S","family":"Kim","sequence":"first","affiliation":[{"name":"Cancer Ecosystems Program, Garvan Institute of Medical Research , Sydney, NSW 2010,","place":["Australia"]},{"name":"Faculty of Medicine and Health, St Vincent\u2019s Clinical School, UNSW Sydney , Sydney, NSW 2010,","place":["Australia"]},{"name":"Faculty of Medicine and Health, University of Sydney , Sydney, NSW 2006,","place":["Australia"]},{"name":"Department of Diabetes and Endocrinology, Westmead Hospital , Sydney, NSW 2145,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria E","family":"Taylor","sequence":"additional","affiliation":[{"name":"Cancer Ecosystems Program, Garvan Institute of Medical Research , Sydney, NSW 2010,","place":["Australia"]},{"name":"Faculty of Medicine and Health, University of Sydney , Sydney, NSW 2006,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Castro-Martinez","sequence":"additional","affiliation":[{"name":"Cancer Ecosystems Program, Garvan Institute of Medical Research , Sydney, NSW 2010,","place":["Australia"]},{"name":"Cancer Plasticity and Dormancy Program, Garvan Institute of Medical Research , Sydney, NSW 2010,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraj","family":"Dhakal","sequence":"additional","affiliation":[{"name":"Cancer Ecosystems Program, Garvan Institute of Medical Research , Sydney, NSW 2010,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amjad","family":"Zamerli","sequence":"additional","affiliation":[{"name":"Cancer Ecosystems Program, Garvan Institute of Medical Research , Sydney, NSW 2010,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindhu T","family":"Mohanty","sequence":"additional","affiliation":[{"name":"Cancer Ecosystems Program, Garvan Institute of Medical Research , Sydney, NSW 2010,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Xiao","sequence":"additional","affiliation":[{"name":"Cancer Ecosystems Program, Garvan Institute of Medical Research , Sydney, NSW 2010,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija K","family":"Simic","sequence":"additional","affiliation":[{"name":"Cancer Ecosystems Program, Garvan Institute of Medical Research , Sydney, NSW 2010,","place":["Australia"]},{"name":"Department of Pathology, New York University Grossman School of Medicine , New York, NY 10016,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Pantalone","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, University of Sydney , Sydney, NSW 2006,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Chu","sequence":"additional","affiliation":[{"name":"Centre for Children's Bone and Musculoskeletal Health, The Children's Hospital at Westmead , Sydney, NSW 2145,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tegan L","family":"Cheng","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, University of Sydney , Sydney, NSW 2006,","place":["Australia"]},{"name":"Centre for Children's Bone and Musculoskeletal Health, The Children's Hospital at Westmead , Sydney, NSW 2145,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter I","family":"Croucher","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, St Vincent\u2019s Clinical School, UNSW Sydney , Sydney, NSW 2010,","place":["Australia"]},{"name":"Cancer Plasticity and Dormancy Program, Garvan Institute of Medical Research , Sydney, NSW 2010,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline R","family":"Center","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, St Vincent\u2019s Clinical School, UNSW Sydney , Sydney, NSW 2010,","place":["Australia"]},{"name":"Cancer Plasticity and Dormancy Program, Garvan Institute of Medical Research , Sydney, NSW 2010,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8746-5529","authenticated-orcid":false,"given":"Christian M","family":"Girgis","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, University of Sydney , Sydney, NSW 2006,","place":["Australia"]},{"name":"Department of Diabetes and Endocrinology, Westmead Hospital , Sydney, NSW 2145,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M","family":"McDonald","sequence":"additional","affiliation":[{"name":"Cancer Ecosystems Program, Garvan Institute of Medical Research , Sydney, NSW 2010,","place":["Australia"]},{"name":"Faculty of Medicine and Health, St Vincent\u2019s Clinical School, UNSW Sydney , Sydney, NSW 2010,","place":["Australia"]},{"name":"Faculty of Medicine and Health, University of Sydney , Sydney, NSW 2006,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"issue":"8","key":"2025031513015870000_ref1","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"2025031513015870000_ref2","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2025031513015870000_ref3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","article-title":"Final results of the DAPS (denosumab adherence preference satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women","volume":"23","author":"Freemantle","year":"2012","journal-title":"Osteoporos Int"},{"issue":"6","key":"2025031513015870000_ref4","doi-asserted-by":"publisher","first-page":"e10629","DOI":"10.1002\/jbm4.10629","article-title":"Bisphosphonate drug holidays: evidence from clinical trials and real world studies","volume":"6","author":"Wang","year":"2022","journal-title":"JBMR Plus"},{"issue":"8","key":"2025031513015870000_ref5","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1056\/NEJMoa1916525","article-title":"Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates","volume":"383","author":"Black","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"2025031513015870000_ref6","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","volume":"28","author":"McClung","year":"2017","journal-title":"Osteoporos Int"},{"issue":"9","key":"2025031513015870000_ref7","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/jbmr.4335","article-title":"Fractures after denosumab discontinuation: a retrospective study of 797 cases","volume":"36","author":"Burckhardt","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2025031513015870000_ref8","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1007\/s00198-020-05507-9","article-title":"Persistence and adherence to parenteral osteoporosis therapies: a systematic review","volume":"31","author":"Koller","year":"2020","journal-title":"Osteoporos Int"},{"issue":"6","key":"2025031513015870000_ref9","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s11914-022-00756-5","article-title":"Osteoclast recycling and the rebound phenomenon following denosumab discontinuation","volume":"20","author":"Kim","year":"2022","journal-title":"Curr Osteoporos Rep"},{"issue":"5","key":"2025031513015870000_ref10","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00223-020-00785-1","article-title":"Comparative effect of zoledronate at 6 versus 18 months following denosumab discontinuation","volume":"108","author":"Anastasilakis","year":"2021","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"2025031513015870000_ref11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00198-022-06648-9","article-title":"Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study","volume":"34","author":"Tutaworn","year":"2023","journal-title":"Osteoporos Int"},{"issue":"4","key":"2025031513015870000_ref12","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00223-017-0288-x","article-title":"Bone loss after denosumab: only partial protection with zoledronate","volume":"101","author":"Reid","year":"2017","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"2025031513015870000_ref13","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/jbmr.4305","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study","volume":"36","author":"S\u00f8lling","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2025031513015870000_ref14","doi-asserted-by":"publisher","first-page":"e2443899-e","DOI":"10.1001\/jamanetworkopen.2024.43899","article-title":"Zoledronate sequential therapy after denosumab discontinuation to prevent bone mineral density reduction: a randomized clinical trial","volume":"7","author":"Lee","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"10","key":"2025031513015870000_ref15","doi-asserted-by":"publisher","first-page":"e1817","DOI":"10.1210\/clinem\/dgae224","article-title":"Zoledronate after denosumab discontinuation: is repeated administrations more effective than single infusion?","volume":"109","author":"Grassi","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2025031513015870000_ref16","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/jbmr.3853","article-title":"Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial","volume":"34","author":"Anastasilakis","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025031513015870000_ref17","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025031513015870000_ref18","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/jbmr\/zjae023","article-title":"Temporal patterns of osteoclast formation and activity following withdrawal of RANKL inhibition","volume":"39","author":"Kim","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2025031513015870000_ref19","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1002\/jbmr.1889","article-title":"Matrix metalloproteinase\u2013driven endochondral fracture union proceeds independently of osteoclast activity","volume":"28","author":"McDonald","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"26","key":"2025031513015870000_ref20","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1182\/blood-2017-03-773341","article-title":"Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma","volume":"129","author":"McDonald","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2025031513015870000_ref21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/jbmr.1805","article-title":"Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry nomenclature committee","volume":"28","author":"Dempster","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2025031513015870000_ref22","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/jbmr.4809","article-title":"Multi-targeting DKK1 and LRP6 prevents bone loss and improves fracture resistance in multiple myeloma","volume":"38","author":"Simic","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2025031513015870000_ref23","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1359\/jbmr.091009","article-title":"Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo","volume":"25","author":"Roelofs","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2025031513015870000_ref24","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2025031513015870000_ref25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11914-017-0380-1","article-title":"Denosumab: an emerging therapy in pediatric bone disorders","volume":"15","author":"Boyce","year":"2017","journal-title":"Cur Osteoporos Rep"},{"issue":"6","key":"2025031513015870000_ref26","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1177\/00099228231194427","article-title":"Hypercalcemia in children following a discontinuation of denosumab therapy: a case report and literature review","volume":"63","author":"Liu","year":"2024","journal-title":"Clin Pediatr"},{"issue":"5","key":"2025031513015870000_ref27","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1007\/s12519-020-00378-w","article-title":"Hypercalcaemia after treatment with denosumab in children: bisphosphonates as an option for therapy and prevention?","volume":"16","author":"Sydlik","year":"2020","journal-title":"World J Pediatr"},{"issue":"3","key":"2025031513015870000_ref28","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00198-022-06651-0","article-title":"Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption","volume":"34","author":"S\u00f8lling","year":"2023","journal-title":"Osteoporos Int"},{"issue":"2","key":"2025031513015870000_ref29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00198-023-06931-3","article-title":"The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injection","volume":"35","author":"Makras","year":"2024","journal-title":"Osteoporos Int"},{"issue":"3","key":"2025031513015870000_ref30","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1210\/endrev\/bnac031","article-title":"Bone turnover markers: basic biology to clinical applications","volume":"44","author":"Schini","year":"2023","journal-title":"Endocr Rev"},{"issue":"11","key":"2025031513015870000_ref31","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1016\/j.jcms.2017.08.011","article-title":"Long-term therapy with intravenous zoledronate increases the number of nonattached osteoclasts","volume":"45","author":"Nagata","year":"2017","journal-title":"J Craniofac Surg"},{"issue":"16","key":"2025031513015870000_ref32","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"9999","key":"2025031513015870000_ref33","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"2025031513015870000_ref34","doi-asserted-by":"publisher","first-page":"e10512","DOI":"10.1002\/jbm4.10512","article-title":"Skeletal responses to romosozumab after 12 months of denosumab","volume":"5","author":"McClung","year":"2021","journal-title":"JBMR Plus"},{"key":"2025031513015870000_ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-024-07139-9","article-title":"A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis","volume":"35","author":"Kumar","year":"2024","journal-title":"Osteoporos Int"},{"issue":"8","key":"2025031513015870000_ref36","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1007\/s00198-022-06386-y","article-title":"Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis","volume":"33","author":"Ebina","year":"2022","journal-title":"Osteoporos Int"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjaf008\/61587978\/zjaf008.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/40\/3\/413\/61587978\/zjaf008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/40\/3\/413\/61587978\/zjaf008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T13:02:39Z","timestamp":1742043759000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/40\/3\/413\/7976670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,1,23]]},"published-print":{"date-parts":[[2025,3,15]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjaf008","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,1,23]]}}}